SEC Comment Letter 0000000000-25-001911 to Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Shuttle Pharmaceuticals Holdings, Inc.
Date: Feb. 19, 2025 · CIK: 0001757499 · Accession: 0000000000-25-001911
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284889
Letter
February 19, 2025 Anatoly Dritschilo, M.D. Chief Executive Officer Shuttle Pharmaceuticals Holdings, Inc. 401 Professional Drive, Suite 260 Gaithersburg, MD 20879 Re:Shuttle Pharmaceuticals Holdings, Inc. Registration Statement on Form S-1 Filed February 13, 2025 File No. 333-284889 Dear Anatoly Dritschilo M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Megan J. Penick, Esq.
Show Raw Text
February 19, 2025
Anatoly Dritschilo, M.D.
Chief Executive Officer
Shuttle Pharmaceuticals Holdings, Inc.
401 Professional Drive, Suite 260
Gaithersburg, MD 20879
Re:Shuttle Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-1
Filed February 13, 2025
File No. 333-284889
Dear Anatoly Dritschilo M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Megan J. Penick, Esq.